Angle Plc (AGL.L) Announced, in its preliminary results for the year ended 30 April 2019, that the revenue rose to £0.678 million from £0.628 million posted in the same period preceding year. The company’s loss before tax stood at £10.87 million, compared to loss of £8.93 million reported in the previous year. The basic and diluted loss per share stood at 6.56p compared to loss per share of 7.91p reported in the previous year. The company’s cash and equivalents stood at £11.01 million.
RNS Number: 2747 H Angle PLC 31 July 2019. Preliminary Results for the year ended 30 April 2019. BUILDING ON A LEADING POSITION IN THE LIQUID BIOPSY MARKET.
Angle Plc (AGL.L) Announced that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet), Duesseldorf, an interdisciplinary team of cancer researchers and clinicians, has published new results in a peer-reviewed journal of work done to develop a "robust, reliable and cost-efficient workflow" for enrichment of single circulating tumor cells (CTCs). This has been published by the DCCNet at the University Hospital and Medical Faculty of the Heinrich-Heine University of Duesseldorf as a peerreviewed publication in the journal Cancers and is available at The researchers combined use of the Parsortix® system with the micromanipulator CellCelector™ to enable single CTCs to be analysed individually to investigate the heterogeneity of the cancer.
Angle PLC (AGL) 71.50p £122m ANGLE, a world-leading liquid biopsy company, announced that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet), Duesseldorf, an interdisciplinary team of cancer researchers and clinicians, has published new results in a peer-reviewed journal of work done to develop a "robust, reliable and cost-efficient workflow" for enrichment of single circulating tumor cells (CTCs). This has been published by the DCCNet at the University Hospital and Medical Faculty of the Heinrich-Heine University of Duesseldorf as a peer-reviewed publication in the journal Cancers and is available at angleplc.com/library/ publications/. The researchers combined use of the Parsortix® system with the micromanipulator CellCelector™ to enable single CTCs to be analysed individually to investigate the heterogeneity of the cancer. They were able to complete PCR-based gene expression analysis of single CTCs processed by Parsortix direct from the patient sample as well as from cells obtained from Parsortix and subsequently cultured outside the patient. This approach may facilitate complex therapeutic decision-making based on the CTC analysis. The work was undertaken in breast cancer and was able to detect varying gene expression between the individual CTCs as well as demonstrating that changes in the patient's HER-2 expression can be detected
ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that one of its leading customers, the Disseminated Cancer Cell Network, Duesseldorf, an interdisciplinary team of cancer researchers and clinicians, has published new results in a peer-reviewed journal of work done to develop a "robust, reliable and cost-efficient workflow" for...
RNS Number: 6673 F Angle PLC 16 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3830 F Angle PLC 12 July 2019. THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.. Capitalised terms not...
RNS Number: 8708 D Angle PLC 28 June 2019. Notification of Preliminary Results and Webcast. A meeting for analysts will be held at 10:30am on 31 July 2019 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4 HD..
RNS Number: 8670 D Angle PLC 28 June 2019 TR-1: S tandard form for notification of major holdings. i Please note that national forms may vary due to specific national legislation as for instance the applicable thresholds or information regarding capital holdings.. Indicate in the relevant section whether the issuer is a non UK issuer..
RNS Number: 4017 D Angle PLC 25 June 2019 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR ANY OTHER JURISDICTION IN WHICH SUCH...
RNS Number: 3207 D Angle PLC 25 June 2019 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR ANY OTHER JURISDICTION IN WHICH SUCH...
Angle Plc (AGL.L) Announced that the leading European cancer centre, University Medical Centre Hamburg-Eppendorf (UKE) has published results of work demonstrating, that the company’s ParsortixTM system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non-small cell lung cancer (NSCLC) patients.
Potential for use of Parsortix as treatment selection biomarker in assessing patient response to cancer immunotherapy drugs with revenues forecast to exceed US$ 20 billion this year. Expression of the protein PD-L1 in cancer cells is of particular importance as PD-L1, and PD-1 the protein to which it binds, are the key targets for leading immunotherapy drugs,...
Angle (AGL.L) 69p £99.72m The liquid biopsy company, announced that the first phase of its ovarian cancer clinical verification study has reported positive results. The pre-study, undertaken by Dr. Richard Moore and colleagues at the University of Rochester Medical Center Wilmot Cancer Institute (Rochester), was designed to evaluate the use of ANGLE's modified and further optimised ParsortixTM and HyCEADTM Ziplex® platfor-ms as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass, in a clinical setting and with clinical samples. The pre-study results demonstrate that the optimisation of the sample-to-answer molecular solution has been successful, paving the way to initiate the 200 subject ovarian cancer clinical verification study of patients who are presenting with a pelvic mass and scheduled for surgery. A positive outcome from the clinical verification study would support ANGLE's plans to launch a clinical assay for the detection of ovarian cancer in women with an abnormal pelvic mass. This study is expected to start in early Q3 CY19 and is projected to complete in Q1 CY20.
Angle Plc (AGL.L) Announced that the first phase of its ovarian cancer clinical verification study has reported positive results. The pre-study results demonstrate that the optimisation of the sample-to-answer molecular solution has been successful, paving the way to initiate the 200 subject ovarian cancer clinical verification study of patients who are presenting with a pelvic mass and scheduled for surgery. This study is expected to start in early Q3 CY19 and is projected to complete in Q1 CY20.
RNS Number: 1523 B Angle PLC 05 June 2019 ANGLE plc. SUCCESSFUL COMPLETION OF OVARIAN CANCER PRE-STUDY. Pre-study demonstrates ANGLE's optimised sample-to-answer molecular solution with patient samples.
Angle Plc (AGL.L) Announced positive results from its Parsortix FDA clinical study for metastatic breast cancer. The Study has achieved its primary objective to demonstrate the ability of the Parsortix system to capture and harvest cancer cells from the blood of a significant proportion of metastatic breast cancer patients.
RNS Number: 6723 A Angle PLC 31 May 2019 ANGLE plc. POSITIVE RESULTS FROM FDA CLINICAL STUDY. Analytical studies ongoing to support FDA submission.
RNS Number: 1692 X Angle PLC 26 April 2019 ANGLE plc. BREAKTHROUGH RESEARCH USING THE PARSORTIX SYSTEM DISCOVERS ROLE OF BODY'S OWN IMMUNE SUPPRESSOR CELLS IN PROMOTING CANCER METASTASIS. The research, led by Professor Dario Marchetti at the Biomarker Research Program, Houston Methodist Research Institute in conjunction with the Center for Precision...
Angle Plc (AGL.L) Announced that top US cancer centre, the University of Texas MD Anderson Cancer Center has developed a new technique for assessing the metastatic potential of breast cancer using the company's ParsortixTM system. The technique Transmembrane Receptor Dynamics (TReD) measures the dynamics of cytoskeletal structure and mechanical properties of live cancer cells held within the microfluidic Parsortix cassette using an optical interrogation technique. The development work has been published in the peer-reviewed publication, Nature. The publication states that the TReD approach can serve "as a new biophysical marker to probe the metastatic potential of cancer cells and even to monitor the transition of metastasis". This offers the potential to differentiate highly invasive cancer cells from non to less-invasive cancer cells allowing more personalised treatment to be offered to the patient.
ANGLE Plc
AGL.L
ANGLE Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    143.49M

Income Statement

Sales/Revenue
Gross Income
Operating Income
Net Interest Income
Pre-Tax Income
Consolidated Net Income
Non-Interest Income
Interest Income after Loan Loss Provision
Non-Operating Income
Operating Income (EBIT)
Net Income
Non-Interest Expense
Operating Expenses
Total Expense
Operating profit per share
EPS (Basic)
EPS (Diluted - Before Unusual Expense)
EPS (Fully Diluted)

Balance Sheet - Assets

Net Property, Plant & Equipment
Intangible Assets
Cash & Short Term Investments
Investments
Other Financial Assets
Inventories
Total Short Term Accounts Receivable
Total Accounts Receivable
Total Cash & Due from Banks
Premium Balance Receivables
Total Current Assets
Tangible Other Assets
Other Intangible Assets
Other Assets
Other Funds
Total Assets

Balance Sheet - Liabilities

Liabilities & Stockholders' Equity
Other Current Liabilities
Total Current Liabilities
Provision for Risks & Charges
Losses, Claims & Reserves
Other Liabilities
Total Liabilities

Balance Sheet - Other

Dividends Per Share (Gross)
Dividends Per Share
Dividends Per Share (1-yr Annual Growth)
Dividend payout per share
Common Shares
Common Shares Outstanding
Common Shares (EPS Basic)
Common Shares (EPS Diluted)
Closely Held Shares
Total Shareholders' Equity
Non-Equity Reserves
Retained Earnings
Total Equity
Pre-Tax Margin
Net Interest Margin
Gross Profit Margin
Net Margin
Operating Margin
P/E Ratio
Debt / EBITDA
Total Debt / Assets
Assets Per Employee
Current Ratio
Common Stock Par / Carry Value
Enterprise Value
Market Value
Market Capitalisation
Dividend Yield
Dividend Yield - Security
Cash Dividend Coverage Ratio

Miscellaneous

Total Debt
Restricted Cash
Exchange Rate Effect
Incomes Taxes
Net Change in Cash
Income Tax Payable
Cash Only
Cash Dividends Paid
Convertible Debt
Long Term Debt
Short Term Debt
Asset Turnover
EBITDA
Operating Income After Interest Expense
Net Debt
Operating Income Before Interest Expense
Purchase / Sale of Investments
Other Appropriated Reserves
Creditors
Watchlist